Test Directory

Home Test Search Results CXCL9 Level
CXCL9 Level

Justification

HLH is a life-threatening condition requiring rapid diagnosis and treatment. CXCL9 can differentiate HLH from sepsis and persistent systemic inflammatory response syndrome (SIRS). CXCL9 levels quickly and significantly decreased with emapalumab treatment in HLH patients and low levels of CXCL9 were associated with treatment response. Emapalumab neutralizes IFNγ activity; CXCL9 is a marker for IFNγ activity.

STAT: < 24 hours (7 days a week)

ELISA

Draw Tube: Purple Top

Sample Type: EDTA Plasma

Specimen Requirements

Sample Type Volume Required Minimum Volume Stability
PREFERRED EDTA Plasma 1mL 0.5mL Frozen (-20C): 2 weeks
Frozen (-80C): 6 months
ALTERNATIVE - - - -
REJECTION CRITERIA Thawed in transit, refrozen or clotted sample
SPECIAL INSTRUCTIONS -

General Information

METHODOLOGY ELISA
STAT TAT < 24 hours (7 days a week)
STAT TAT Performance > 90% of results released in 20 hours 7 days a week
ROUTINE TAT < 1 week
ALTERNATIVE NAMES C-X-C Motif Chemokine Ligand 9, CXCL-9, MIG, Monokine Induced by Gamma Interferon
DESCRIPTION Chromogenic ELISA for the quantitative measurement of CXCL9 in human plasma.
LIMITATIONS -
NORMAL RANGE < 180pg/mL
ASSOCIATED TESTING -
REFERENCES

1. Lin H, et al. Blood Adv (2021) 5 (17): 3457-3467.
2. Maruoka H, et al. Ann Hematol. 2014 Mar;93(3):393-401.
3. Locatelli F, et al. N Engl J Med. 2020;382(19):1811.
4. Jordan MB, et al. Blood. 2011;118(15):4041.
SAMPLE REPORT Upon request
NEW YORK STATE APPROVED Yes

Test Codes

ORDER CODE P3420
CPT CODE 83520
LOINC CODE 98115-9